1. BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (June 2017) Authors: Trotman, J.; Opat, S.; Marlton, P.; Gottlieb, D.; Simpson, D.; Cull, G.; Ritchie, D.; Verner, E.; Ratnasingam, S.; Anderson, M.; Wood, P.; Wang, L.; Xue, L.; Hedrick, E.; Huang, J.; Hilger, J.; Seymour, J.F.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Frequency of bowel perforation and impact of bowel rest in aggressive non‐Hodgkin lymphoma with gastrointestinal involvement. (20th April 2018) Authors: Chin, C. K.; Tsang, E.; Mediwake, H.; Khair, W.; Biccler, J.; Hapgood, G.; Mollee, P.; Nizich, Z.; Joske, D.; Radeski, D.; Cull, G.; Villa, D.; El‐Galaly, T. C.; Cheah, C. Y. Journal: British journal of haematology Issue: Volume 184:Number 5(2019) Page Start: 826 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FREQUENCY OF PERFORATION & IMPACT OF BOWEL REST IN AGGRESSIVE NON‐HODGKIN LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT: AN INTERNATIONAL, MULTI‐CENTER RETROSPECTIVE STUDY. (June 2017) Authors: Chin, C.K.; Tsang, E.; Mediwake, H.; Khair, W.; Biccler, J.L.; El‐Galaly, T.C.; Hapgood, G.; Mollee, P.; Villa, D.; Nizich, Z.; Joske, D.; Radeski, D.; Cull, G.; Cheah, C.Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) Authors: Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; Kim, W.; Wang, L.; Xue, L.; Hilger, J.; Huang, J.; Hedrick, E.; Roberts, A.W.; Tam, C.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). (23rd June 2022) Authors: Dimopoulos, M.; Opat, S.; D'Sa, S.; Jurczak, W.; Lee, H.-P.; Cull, G.; Owen, R. G.; Marlton, P.; Wahlin, B. E.; Garcia-Sanz, R.; McCarthy, H.; Mulligan, S.; Tedeschi, A.; Castillo, J. J.; Czyz, J.; Fernandez De Larrea Rodriguez, C.; Belada, D.; Libby, E.; Matous, J.; Motta, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY. (23rd June 2022) Authors: Doorduijn, J.; Issa, S.; van der Holt, B.; Minnema, M.; Seute, T.; Durian, M.; Cull, G.; van der Poel, M.; Stevens, W.; Zijlstra, J.; Nijland, M.; Mason, K.; Beeker, A.; Brandsma, D.; van den Bent, M.; Gonzalez, M.; de Jong, D.; Bromberg, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1062 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prognostic nomogram for diffuse large B‐cell lymphoma incorporating the International Prognostic Index with interim‐positron emission tomography findings. Issue 8 (6th August 2013) Authors: Chow, A.; Phillips, M.; Siew, T.; Cull, G.; Augustson, B.; Ward, M.; Joske, D. Journal: Internal medicine journal Issue: Volume 43:Issue 8(2013) Page Start: 932 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). (12th June 2019) Authors: Tam, C.S.; Wang, M.; Simpson, D.; Opat, S.; Cull, G.; Munoz, J.; Phillips, T.J.; Kim, W.; Atwal, S.; Wei, R.; Huang, J.; Elstrom, R.; Trotman, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗